ישראל - עברית - Ministry of Health

inovamed ltd - lamivudine; zidovudine - טבליות מצופות פילם - lamivudine 150 mg; zidovudine 300 mg - zidovudine

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate; lamivudine - טבליות מצופות פילם - abacavir as sulfate 600 mg; lamivudine 300 mg - nucleoside and nucleotide reverse transcriptase inhibitors - kivexa is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate; lamivudine - טבליות מצופות פילם - abacavir as sulfate 600 mg; lamivudine 300 mg

ישראל - עברית - Ministry of Health

bristol - myers squibb, israel - entecavir; entecavir - טבליות מצופות פילם - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - maraviroc - טבליות מצופות פילם - maraviroc 150 mg - maraviroc - maraviroc - celsentri is a ccr5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only ccr5-tropic hiv-1.• in treatment-na?ve subjects, more subjects treated with celsentri experienced virologic failure and developed lamivudine resistance compared to efavirenz.• tropism testing with a highly sensitive tropism assay is required for the appropriate use of celsentri.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - maraviroc - טבליות מצופות פילם - maraviroc 300 mg - maraviroc - maraviroc - celsentri is a ccr5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only ccr5-tropic hiv-1.• in treatment-na?ve subjects, more subjects treated with celsentri experienced virologic failure and developed lamivudine resistance compared to efavirenz.• tropism testing with a highly sensitive tropism assay is required for the appropriate use of celsentri.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate 300 mg; lamivudine 150 mg - tablets - zidovudine - for the treatment of human immunodeficiency virus (hiv) infected adults.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - adefovir dipivoxil - טבליה - adefovir dipivoxil 10 mg - adefovir dipivoxil - adefovir dipivoxil - hepsera is indicated for the treatment of chronic hepatitis b in adults with evidence of hepatitis b viral replication. reductions in viral replication and improvements in liver function have also been demonstrated in supportive studies in a limited number of chronic hepatitis b patients with genotypic evidence of lamivudine-resistance, including patients with compensated or decompensated liver disease and patients co-infected with hiv.

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited - entecavir 1 mg - film coated tablets - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme